Viridian Therapeutics (VRDN) to Release Earnings on Wednesday

Viridian Therapeutics (NASDAQ:VRDN) will likely be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect Viridian Therapeutics to post earnings of ($0.95) per share and revenue of $0.04 million for the quarter.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.08. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Viridian Therapeutics Stock Up 5.9%

VRDN opened at $13.12 on Tuesday. The company has a 50 day moving average of $13.66 and a 200 day moving average of $17.37. The company has a market cap of $1.07 billion, a PE ratio of -3.04 and a beta of 0.57. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. The Goldman Sachs Group cut their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Needham & Company LLC cut their price target on shares of Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. JMP Securities cut their price target on shares of Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a report on Wednesday, May 7th. Finally, Royal Bank of Canada cut their price target on shares of Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, Viridian Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $36.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.